Publication:
Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 Фармакоэпидемиологическое исследование COVID-19 в Россиискои Федерации ЭГИДА-2020

Простая страница элемента
dc.contributor.authorPshenichnaya, N. Yu.
dc.contributor.authorKareva, E. N.
dc.contributor.authorLeneva, I. A.
dc.contributor.authorBulgakova, V. A.
dc.contributor.authorPetrov, V. A.
dc.date.accessioned2024-11-30T02:46:23Z
dc.date.available2024-11-30T02:46:23Z
dc.date.issued2021
dc.description.abstract© 2021 Consilium Medikum. All rights reserved.Background. During 2020 a several antiviral drugs were recommended in Russia, therefore issue of COVID-19 antiviral therapy (AVT) remains open. Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age - 48.7±18.1 (median - 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median - 54 vs 21 years; p<0.001), higher body mass index (27.8 vs 23.4; p<0.001), prevalence of chronic diseases (75.3% vs 8.5%; p<0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.8±6.1 vs 4.2±2.7 days; p<0.001) and catarrhal symptoms duration (10.2±5.4 vs 6.1±4.1 days; p<0.001). Results. During hospitalization 92% of the patients received AVT, 77% - antibiotics, and 16% - corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.7±5.5 vs 11.7±5.5 days; p<0.001) and catarrhal symptoms duration (8.8±5.1 vs 12.0±4.9 days; p<0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.9±7.5 vs 11.7±5.5; p<0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.
dc.format.extentС. 1306-1315
dc.identifier.citationPharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 Фармакоэпидемиологическое исследование COVID-19 в Россиискои Федерации ЭГИДА-2020 / Pshenichnaya, N.Yu. [et al.] // Terapevticheskii Arkhiv. - 2021. - 93. - № 11. - P. 1306-1315. - 10.26442/00403660.2021.11.201206
dc.identifier.doi10.26442/00403660.2021.11.201206
dc.identifier.urihttps://www.doi.org/10.26442/00403660.2021.11.201206
dc.identifier.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85124221261&origin=resultslist
dc.identifier.urihttps://openrepository.mephi.ru/handle/123456789/25305
dc.relation.ispartofTerapevticheskii Arkhiv
dc.titlePharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 Фармакоэпидемиологическое исследование COVID-19 в Россиискои Федерации ЭГИДА-2020
dc.typeArticle
dspace.entity.typePublication
oaire.citation.issue11
oaire.citation.volume93
relation.isOrgUnitOfPublication4b108cd7-08a1-4350-ab3f-20450dec091d
relation.isOrgUnitOfPublication.latestForDiscovery4b108cd7-08a1-4350-ab3f-20450dec091d
Файлы
Коллекции
Публикации